The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy

The Prostate ◽  
2015 ◽  
Vol 75 (14) ◽  
pp. 1499-1509 ◽  
Author(s):  
Kasper D. Berg ◽  
Martin A. Røder ◽  
Frederik B. Thomsen ◽  
Ben Vainer ◽  
Thomas A. Gerds ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Protein Expression ◽  
Androgen Deprivation Therapy ◽  
Predictive Value ◽  
Advanced Prostate Cancer ◽  
Androgen Deprivation ◽  
Castration Resistant Prostate Cancer ◽  
Primary Androgen Deprivation Therapy ◽  
Castration Resistant ◽  
Primary Androgen Deprivation

Alkaline phosphatase (ALP) value at diagnosis of CRPC and response to primary androgen deprivation therapy may predict metastasis in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 294-294
Author(s):  
Mori Keiichiro ◽  
Takahiro Kimura ◽  
Shin Egawa
Keyword(s):  
Prostate Cancer ◽  
Multivariate Analysis ◽  
Retrospective Study ◽  
Androgen Deprivation Therapy ◽  
Therapeutic Options ◽  
Castration Resistant Prostate Cancer ◽  
Aggressive Therapy ◽  
Primary Androgen Deprivation Therapy ◽  
Castration Resistant ◽  
Primary Androgen Deprivation

294 Background: Numerous therapeutic options are available for metastatic castration-resistant prostate cancer (mCRPC). However, current therapeutic options remain inadequate for non-metastatic CRPC (nmCRPC); furthermore, there is a paucity of clear evidence to show who may be targeted for aggressive therapy among nmCRPC patients. Therefore, the objective of this retrospective study was to explore predictors of metastasis in patients with nmCRPC and to identify a subpopulation of nmCRPC patients who may benefit from aggressive therapy. Methods: A total of 115 patients with CRPC who had no metastasis at the time of diagnosis of CRPC were included in this retrospective study. All patients were treated at Jikei University Hospital. The primary outcome measure was metastasis-free survival (MFS) from the time of diagnosis of CRPC. Predictors of MFS were also explored with a multivariate Cox model. Results: The median observation period after diagnosis of CRPC in these patients was 30 months. Kaplan-Meier analysis revealed a median MFS of 76 months in these patients. Multivariate analysis demonstrated that low ALP values at diagnosis of CRPC and favorable response to primary androgen deprivation therapy (ADT) were significant predictors of longer MFS ( P = 0.011, and 0.031, respectively). Conclusions: Study results suggest that high ALP values at diagnosis of CRPC and poor response to primary ADT may predict metastasis in patients with nmCRPC. Further prospective studies will be required in more patients to confirm our findings. Univariate/multivariate analysis of factors contributing to MFS in nmCRPC patients. [Table: see text]

scholarly journals Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

2020 ◽  
Vol 12 ◽  
pp. 175883592097813
Author(s):  
Pernelle Lavaud ◽  
Clément Dumont ◽  
Constance Thibault ◽  
Laurence Albiges ◽  
Giulia Baciarello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Receptor ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Next Generation ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Castration Resistant ◽  
Recent Advances

Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in these patients is a major issue, several trials have investigated next-generation androgen receptor (AR) axis inhibitors such as apalutamide, darolutamide, and enzalutamide in this setting. This review summarizes the recent advances in the management of nmCRPC, highlighting the favourable impact of next-generation AR inhibitors on metastases-free survival, overall survival and other clinically meaningful endpoints.

Sign in / Sign up

Export Citation Format

Share Document